← Oncology Approval Tracker

FDA DECISION ·

Tevimbra

tislelizumab-jsgr · BeOne Medicines USA

FDA approvalNew dosing regimenGastric and gastroesophageal junction cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds 150 mg every two weeks or 300 mg every four weeks with platinum and fluoropyrimidine chemotherapy for adults with previously untreated unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma and tumor PD-L1 expression of at least 1.

LAMPGEN ANALYSIS

Why it matters

The approved alternatives let the checkpoint inhibitor schedule fit different platinum and fluoropyrimidine calendars.

What research teams should watch

Build order sets that distinguish immunotherapy and chemotherapy cycle lengths and document biomarker eligibility.

PRIMARY RECORDS

Sources